EUCTR2017-004896-30-GR进行中（未招募）1 期
A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in Combination with Chemotherapy as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic LAG-3 Positive Gastric or Gastroesophageal Junction Adenocarcinoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Participants must have histologically- or cytologically-confirmed diagnosis of unresectable, locally advanced, or metastatic gastric or GEJ adenocarcinoma
- •- Available tumor tissue for biomarker analysis; participants must have LAG-3 positive expression
- •- Participants must have at least one measurable lesion or evaluable disease by CT or MRI per RECIST 1.1 criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1694
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 726
排除标准
- •- Participants known HER2 positive status
- •- Participants with untreated known CNS metastases
- •- Participants with ascites which cannot be controlled with appropriate interventions
研究者
相似试验
进行中（未招募）
1 期
A study comparing immunotherapy combinations with chemotherapy and chemotherapy alone in participants with advanced LAG-3 positive gastric and gastroesophageal junction (GEJ) cancersEUCTR2017-004896-30-NLBristol-Myers Squibb International Corporation2,420
撤回
3 期
A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS-986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in Combination with Chemotherapy as First-Line Treatment in Participants with Unresectable, Locally Advanced or Metastatic LAG-3 Postive Gastric or Gastroesophageal Junction AdenocarcinomaStomach CancerNL-OMON46592Bristol-Myers Squibb8
招募中
1 期
A study comparing immunotherapy combinations with chemotherapy and chemotherapy alone in participants with advanced LAG-3 positive gastric and gastroesophageal junction (GEJ) cancersEUCTR2017-004896-30-NOBristol-Myers Squibb International Corporation2,420
进行中（未招募）
1 期
A study comparing immunotherapy combinations with chemotherapy and chemotherapy alone in participants with advanced LAG-3 positive gastric and gastroesophageal junction (GEJ) cancersEUCTR2017-004896-30-ESBristol-Myers Squibb International Corporation2,420
进行中（未招募）
1 期
A study comparing immunotherapy combinations with chemotherapy and chemotherapy alone in participants with advanced LAG-3 positive gastric and gastroesophageal junction (GEJ) cancersGastric or Gastroesophageal Junction AdenocarcinomaMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004896-30-PLBristol-Myers Squibb International Corporation2,420